{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:37Z","timestamp":1786118977121,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/coc.0b013e31816d1c7b","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T03:10:36Z","timestamp":1222830636000},"page":"481-487","source":"Crossref","is-referenced-by-count":6,"title":["A Phase II Trial of Fixed-Dosed Rate Gemcitabine in Platinum-Resistant Ovarian Cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Belen Ojeda","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Gonzalez","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Bover","family":"Barcelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Fabregat","family":"i Mayol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jesus Rubio","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Alonso","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Casado","family":"Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Calvo","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Churruca","family":"Galaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angels Arcusa","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Herrero","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna Adrover","family":"Cebrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Poveda","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u2032, 2\u2032-difluorodeoxicytidine) in previously treated ovarian cancer patients.","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1008364327684","article-title":"Phase II study of gemcitabine in ovarian cancer.","volume":"10","author":"von Minckwitz","year":"1999","journal-title":"Ann Oncol"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0923-7534(20)31480-0","article-title":"Use of tumour markers in monitoring the course of ovarian cancer.","volume":"10","author":"Rustin","year":"1999","journal-title":"Ann Oncol"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage design for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1525-1438.2005.00482.x","article-title":"A phase II study of fixed dose rate gemcitabine in patients with relapsed m\u00fcllerian tumors.","volume":"15","author":"Penson","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002800050492","article-title":"Antitumor activity of prolonged as compared with bolus administration of 2\u2032,2\u2032-difluorodeoxycytidine in vivo against murine colon tumors.","volume":"38","author":"Veerman","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1005981317532","article-title":"A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.","volume":"15","author":"Brand","year":"1997","journal-title":"Invest New Drugs"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/annonc\/mdg196","article-title":"Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.","volume":"14","author":"Castellano","year":"2003","journal-title":"Ann Oncol"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2002.20.3.674","article-title":"Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.","volume":"20","author":"Rizzieri","year":"2002","journal-title":"J Clin Oncol"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2002.08.166","article-title":"Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.","volume":"20","author":"Bass","year":"2002","journal-title":"J Clin Oncol"},{"key":"R20-13-20210128","first-page":"663","article-title":"Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.","volume":"9","author":"Rizzieri","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjc.6601369","article-title":"Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.","volume":"89","author":"Guan","year":"2003","journal-title":"Br J Cancer"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2006.03.004","article-title":"A randomized phase II trial evaluating standard (50 mg\/min) versus low (10 mg\/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.","volume":"52","author":"Cappuzzo","year":"2006","journal-title":"Lung Cancer"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.11501","article-title":"Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.","volume":"98","author":"Ceribelli","year":"2003","journal-title":"Cancer"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdl084","article-title":"A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.","volume":"17","author":"Soo","year":"2006","journal-title":"Ann Oncol"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Doxil Study 30\u201349 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory ovarian cancer.","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomised phase II study of the EORTC of Cancer Gynecology Group.","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/gyno.1998.5237","article-title":"Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.","volume":"72","author":"Bolis","year":"1999","journal-title":"Gynecol Oncol"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","article-title":"Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G. O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group.","volume":"90","author":"Buda","year":"2004","journal-title":"Br J Cancer"},{"issue":"suppl 3","key":"R38-13-20210128","first-page":"S241","article-title":"Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy.","volume":"15","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/14737140.4.6.1125","article-title":"Medical treatment of epithelial ovarian cancer.","volume":"4","author":"Gonzalez-Martin","year":"2004","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-200810000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:12:58Z","timestamp":1786036378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200810000-00013"}},"subtitle":["A GEICO (Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Ovario) Trial"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31816d1c7b","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}